Quantitative sensory testing was used to assess the prevalence of sensory dysfunction in patients with cancer, carefully screened for other risk factors for neuropathy. Large fibre type sensory function was evaluated using vibration threshold (VT) determinations while small fibre type sensory function was assessed by thermal threshold (TT) determinations. Mean VT and TT were significantly elevated in the toes but not the fingers of cancer patients. VT elevations in the toes occurred in 31% of cancer patients and in 6% of control subjects. TT limited by several important factors. First, a number of patients with diabetes, alcoholism, or a history of treatment with neurotoxic chemotherapeutic agents were included. Second, VTs were determined only in the upper extremity. Studies of the lower extremity might dramatically increase the yield, since axonopathies affect peripheral nerves in proportion to their length. Third, the study assessed large fibre type function using VT but did not evaluate small fibre type function. Small fibre dysfunction can now be assessed using a psychophysical method to determine the thermal threshold (TT). This measure reflects the functional status of small nerve fibres and the spino-thalamic pathways with which they interact.'92' To address these issues we have determined both VT and TT in the hands and feet of cancer patients free of identifiable risk factors for neuropathy. A control population consisting of 100 healthy subjects, who ranged in age from 27-76 years and were free of alcoholism, diabetes and history of neurological disease was tested using the same procedures.
In an earlier report, we used quantitative sensory testing (QST) to screen a cancer population for large fibre type sensory dysfunction. 22 Specifically, we measured vibration threshold (VT), which reflects function in large diameter, heavily myelinated peripheral nerves and the dorsal column medial lemniscal system with which they interact.'7'9 We found significant VT elevations in 12% of cancer patients and only 1 7% of control subjects. VT elevations were statistically related to the presence of a neoplasm rather than to identifiable risk factors for neuropathy. Although this study demonstrated the potential utility of QST in assessing sensory function in cancer patients it was limited by several important factors. First, a number of patients with diabetes, alcoholism, or a history of treatment with neurotoxic chemotherapeutic agents were included. Second, VTs were determined only in the upper extremity. Studies of the lower extremity might dramatically increase the yield, since axonopathies affect peripheral nerves in proportion to their length. Third, the study assessed large fibre type function using VT but did not evaluate small fibre type function. Small fibre dysfunction can now be assessed using a psychophysical method to determine the thermal threshold (TT). This measure reflects the functional status of small nerve fibres and the spino-thalamic pathways with which they interact.'92' To address these issues we have determined both VT and TT in the hands and feet of cancer patients free of identifiable risk factors for neuropathy. Table 3 shows that the proportion of subjects with small fibre type sensory dysfunction was significantly greater in cancer patients than in Table I 2Two of the patients with cancer had thermal thresholds in toe which exceeded 15'C, the maximum of the test. These individuals were assigned the value of 150C. VT elevation is most likely to be the psychophysical correlate of the previously described structural and electrophysiological abnormalities of peripheral nerve, associated with cancer.68 In our previous report, 12% of patients had a large fibre type sensory dysfunction, defined by VT in the finger which exceeded the mean of age-matched controls by two SD. 22 In this study, 6-9% of subjects had finger VT elevations which exceeded this standard. Large fibre type sensory dysfunction was much more common in the toes than in the fingers; examination of the lower extremity probably yields a more accurate estimate of the prevalence of this abnormality, as expected if it reflects a length dependent axonopathy.
Subclinical small fibre type function has not been previously assessed in cancer patients. TT is most likely the psychophysical correlate of small fibre function, predominantly of the A-delta small myelinated type.23 In this study, seven of 14 (50%) cancer patients had a small fibre type dysfunction, occurring in the toe in six of the seven patients. The striking proportion of patients with TT elevations suggests that small fibre neuropathy may be commonly associated with cancer. The majority of patients with small fibre type sensory dysfunction did not have large fibre dysfunction, suggesting that these phenomena may be independent. However, both patients with large fibre dysfunction, that also had small fibre function measured, exhibited small fibre abnormalities, whereas the converse was not true; five of fourteen patients (35-7%) had abnormal small fibre function in the toe with normal large fibre function. Standard electrophysiological procedures assess only large, not small fibre function, and therefore cannot be used to confirm these results.
The results cannot be attributed to nonspecific phenomena, such as lack ofmotivation, inattention or medication effects because subjects with vibration threshold abnormalities in the feet often had normal vibration thresholds in the hands and normal thermal thresholds. These nonspecific phenomena would be expected to impair thresholds on all tests performed.
These findings must be interpreted cautiously. Replication in a larger sample is needed. Moreover, QST does not differentiate functional derangements at various levels ofthe afferent pathway. Though it has been widely used to screen for neuropathy, abnormalities in some patients may reflect disease of the central somatosensory pathways. Finally, patients with elevated sensory thresholds did not receive additional evaluation. It would be helpful to evaluate these patients with routine nerve conduction studies and to obtain additional nutritional assessments.
Notwithstanding these caveats, this study confirms that VT are elevated in a significant proportion of cancer patients and that the proportion is greater when the lower extremity is studied. TT are also elevated in a significant proportion of patients with cancer, suggesting that small as well as large fibre neuropathy may occur in these patients. Finally, by studying patients carefully screened to eliminate other identifiable causes of neuropathy, these data support the hypothesis that sensory dysfunction may be directly related to an effect of the neoplasm, or an as yet unidentified variable strongly associated with neoplasm. Additional studies using QST in combination with nerve conduction studies, metabolic and nutritional assessment, as well as immunological studies may help to further define the prevalence, pattern and aetiology of neuropathy in patients with cancer.
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